Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

Add GALT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/22/2017 12:04:11 PM - Followers: 76 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:




Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.




Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017 11/13/2017 09:00:00 AM
GALT News: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment ... 11/13/2017 08:30:00 AM
GALT News: Current Report Filing (8-k) 11/13/2017 08:20:13 AM
GALT News: Proxy Statement (definitive) (def 14a) 11/07/2017 04:32:36 PM
GALT News: Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update 11/07/2017 08:15:00 AM
#3231   Good call. Nice to have an expert here... Darwinian 11/22/17 12:04:11 PM
#3230   Some of the run up players exited. biotechexpert 11/22/17 12:06:25 AM
#3229   What happened today? Did the results leaked and they Amatuer17 11/21/17 05:43:43 PM
#3228   CELG big drop in stock price. Question. Dr. rickyricks 10/28/17 01:40:23 PM
#3227   With limited time lately, I briefly looked for sokol 10/25/17 08:06:43 PM
#3226   Did you see poster for the session? It will Amatuer17 10/22/17 07:45:19 PM
#3225   Galectin Therapeutics to Present Clinical Data at The sokol 10/21/17 09:09:46 AM
#3224   Czirr did not disclose transferring hundreds of thousands KnokKnok 10/15/17 09:29:57 AM
#3223   Traber and his expensive Elvis suit! zest 10/02/17 05:24:52 PM
#3222   Traber and his Elvis suit! zest 10/02/17 03:38:58 PM
#3221   I'm not friends/family or an investor in the biotech2010 10/02/17 02:09:59 PM
#3220   Yes The 10 X fund/Jim Czirr sold people KnokKnok 10/02/17 10:11:39 AM
#3219   Traber has full responsibility for all the screw biotech2010 10/02/17 07:21:52 AM
#3218   The 10X Fund has been a key investor biotech2010 10/02/17 07:20:56 AM
#3217   “ The Reporting Persons acquired their interests in Amatuer17 10/01/17 11:45:41 PM
#3216   He did not buy 14 million shares now. KnokKnok 10/01/17 08:23:40 PM
#3215   The Dec results for the co is a Amatuer17 10/01/17 06:32:11 PM
#3214   I'm not sure whether the one responsible for thefamilyman 10/01/17 12:55:05 PM
#3213   The present board removed Czirr from Chair so KnokKnok 09/28/17 11:19:21 AM
#3212   Certainly in the sense the FX trial failed. gss2003 09/28/17 10:06:40 AM
#3211   I bought 2500 shares of GALT yesterday at biotech2010 09/28/17 07:14:17 AM
#3210   Buddies in the biz are saying $20/shr upside, goingforittoday 09/27/17 08:43:29 PM
#3209   Someone bought a ton of shares yesterday but jmh0602 09/27/17 02:51:30 PM
#3208   Yes, they will begin the analysis at that gss2003 09/26/17 02:42:14 PM
#3207   What does it mean that the "Blinded data IRAHopeful 09/26/17 02:19:43 PM
#3206   Had not seen the last 10-k when 10x Amatuer17 09/23/17 10:16:37 PM
#3205   The 10-k and attached letter is interesting. Amatuer17 09/23/17 10:03:06 PM
#3204   I wondered whether it was Traber or Czirr thefamilyman 09/23/17 06:30:20 PM
#3203   How do you interpret a fail in the jmh0602 09/23/17 04:00:12 PM
#3202   I only interpret that they expect the study gss2003 09/23/17 12:43:39 PM
#3201   The level of risk in NASH studies AGN acquired Amatuer17 09/23/17 07:27:31 AM
#3200   That is an interesting 8-K... thefamilyman 09/22/17 11:42:12 PM
#3199   Did ChessMaster bail on it too, like gss2003 09/19/17 08:19:02 PM
#3198   Completely agree on downside and more possibility of Amatuer17 09/19/17 07:21:57 PM
#3197   I had sold my last shares in May biotech2010 09/19/17 11:15:18 AM
#3196   The upside is worth the risk on this one! BIGT80 09/15/17 10:04:12 PM
#3195   GALT financials O/s shares - 34 million Warrants/stock options - Amatuer17 09/14/17 10:04:28 PM
#3194   Actually I went with Jan 2018 options based Amatuer17 09/14/17 03:20:05 PM
#3193   Stock is $1.67 gss2003 09/14/17 12:47:23 PM
#3192   Company is maintaining the Dec 2017 deadline as Amatuer17 09/14/17 11:23:03 AM
#3191   Is it December yet? Noticed the short jmh0602 09/13/17 12:39:55 PM
#3190   "Pfizer has started testing an experimental medicine for Amatuer17 08/29/17 11:33:33 PM
#3189   we don't have a partner for psoriasis so jmh0602 08/21/17 06:09:15 PM
#3188   Was the reference to the 3 AD patients gss2003 08/18/17 10:12:06 AM
#3187   It really depends on how well it works. gss2003 08/17/17 08:15:34 PM
#3186   Realistically probably 10 billion. Share price well biotechexpert 08/16/17 07:26:09 PM
#3185   Early 2018 for combo therapy next readout, after gss2003 08/16/17 03:30:13 PM
#3184   How much is the company worth if the jmh0602 08/16/17 01:52:31 PM
#3183   Thera are also melanoma results coming. I think Coolec78 08/15/17 07:11:42 PM
#3182   Doesn't seem very encouraging given the longs are gss2003 08/15/17 10:40:40 AM